Incyte sets next earnings date, analyst views frame the stock context
24.06.2026 - 11:07:31 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 11:00.
Incyte (US45337C1027) trades on NASDAQ as a mid-cap biotech focused on immunology and oncology. The next earnings date is currently indicated as July 28, 2026, giving investors a clear timetable for the upcoming quarterly update on the US exchange.
What current data shows
Recent data from TrendSpider points to Incyte shares around the 104 dollar mark, with the stock up roughly 7.5 percent over the past 30 days, a move that reflects above-average trading volume in that period. This places Incyte alongside US biotech peers such as Vertex Pharmaceuticals and Regeneron in a sector that has seen selective strength in 2026.
For the upcoming quarter, market participants will closely watch revenue trends in core franchises and any commentary on research and development spending, as these elements have been central to prior earnings calls. The July 28 date frames when fresh details on margins and pipeline progress are expected to be released to NASDAQ investors.
Analyst stance on the shares
Oppenheimer analyst Jay Olson recently maintained a Perform rating on Incyte and raised the price target from 84 to 90 dollars, according to data summarized by TrendSpider. This adjustment signals a modestly more constructive view on valuation while keeping the rating neutral, and it adds to a broader consensus picture in which the stock is neither a clear overweight nor an underweight.
Retail investors often pair such individual analyst moves with aggregated consensus metrics from platforms like MarketScreener and other research aggregators, which list the distribution of Buy, Hold and Sell ratings as well as average price targets for NASDAQ-listed biotech names. These consensus snapshots provide context around how Incyte is viewed relative to sector peers in the S&P 500 health care universe.
All news and analysis on the Incyte shares
More background, filings and price data on the Incyte stock are available in the dedicated topic section and via the company’s Investor Relations page.
The product behind the stock
Incyte generates most of its revenues from Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor co-marketed with Novartis for myelofibrosis and polycythemia vera, alongside other indications. The company also has a growing portfolio of oncology and inflammation assets, with multiple clinical-stage candidates in immuno-oncology and dermatology contributing to its longer-term pipeline value.
Where the stock trades today
The Incyte shares (US45337C1027) last traded on NASDAQ at approximately 104.40 US dollars as of 2026-06-23, 16:00 Eastern Time, based on TrendSpider market data.
Key data on the Incyte shares
- Company: Incyte Corporation
- ISIN: US45337C1027
- WKN: 896133
- Ticker: INCY
- Trading venue: NASDAQ
- Price (as of 2026-06-23, 16:00): 104.40 USD
- Market cap: around 23 billion USD (as of 2026-06-23, based on prevailing share price and shares outstanding).
- Sector / industry: Health Care / Biotechnology
- Index membership: S&P 500 Health Care sector
- Next earnings date: 2026-07-28
Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or an invitation to make any other specific financial decision.
